MEDCL Stock Overview
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
MedinCell S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €18.06 |
52 Week High | €18.74 |
52 Week Low | €5.25 |
Beta | 1.18 |
11 Month Change | 23.36% |
3 Month Change | 18.82% |
1 Year Change | 160.23% |
33 Year Change | 85.80% |
5 Year Change | 150.83% |
Change since IPO | 145.71% |
Recent News & Updates
Recent updates
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
Jul 05Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Apr 26Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
Jan 09The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
Mar 02Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Jan 08Shareholder Returns
MEDCL | FR Pharmaceuticals | FR Market | |
---|---|---|---|
7D | -1.3% | 3.1% | 0.2% |
1Y | 160.2% | 3.8% | 1.4% |
Return vs Industry: MEDCL exceeded the French Pharmaceuticals industry which returned 5.5% over the past year.
Return vs Market: MEDCL exceeded the French Market which returned 1.5% over the past year.
Price Volatility
MEDCL volatility | |
---|---|
MEDCL Average Weekly Movement | 5.9% |
Pharmaceuticals Industry Average Movement | 4.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in FR Market | 9.6% |
10% least volatile stocks in FR Market | 2.5% |
Stable Share Price: MEDCL's share price has been volatile over the past 3 months.
Volatility Over Time: MEDCL's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 134 | Christophe Douat | www.medincell.com |
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.
MedinCell S.A. Fundamentals Summary
MEDCL fundamental statistics | |
---|---|
Market cap | €525.32m |
Earnings (TTM) | -€25.04m |
Revenue (TTM) | €11.95m |
44.0x
P/S Ratio-21.0x
P/E RatioIs MEDCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MEDCL income statement (TTM) | |
---|---|
Revenue | €11.95m |
Cost of Revenue | €0 |
Gross Profit | €11.95m |
Other Expenses | €36.98m |
Earnings | -€25.04m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Dec 03, 2024
Earnings per share (EPS) | -0.86 |
Gross Margin | 100.00% |
Net Profit Margin | -209.61% |
Debt/Equity Ratio | -151.4% |
How did MEDCL perform over the long term?
See historical performance and comparison